Biogen Inc. (BIIB)

332.87
NASDAQ : Health Technology
Prev Close 324.71
Day Low/High 324.71 / 333.28
52 Wk Low/High 249.17 / 388.67
Avg Volume 1.24M
Exchange NASDAQ
Shares Outstanding 196.71M
Market Cap 63.87B
EPS 21.60
P/E Ratio 15.05
Div & Yield N.A. (N.A)

Latest News

Biogen Rated at BTIG

Biogen's Slump Is Likely to Continue

Biogen's Slump Is Likely to Continue

Avoid the long side of Biogen as the October low is likely to be tested or broken in the days ahead.

The Real Money Post-Industrial Average Has Jumped 11% So Far This Year

The Real Money Post-Industrial Average Has Jumped 11% So Far This Year

For the month of November RMPIA climbed 1.2% month over month.

Real Money Post-Industrial Average Beat Nasdaq Comp in November's First Half

Real Money Post-Industrial Average Beat Nasdaq Comp in November's First Half

Our index of 30 cutting-edge companies fell ... but not as much as the Nasdaq did.

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Straying from these names could land you in quicksand as the 4th quarter begins.

Big Swings in Biogen Make It Hard to Take New Positions

Big Swings in Biogen Make It Hard to Take New Positions

Short-term price action may be volatile, but this name is still bullish long term.

The Race to Cure Alzheimer's is On: These Are the Forerunners

The Race to Cure Alzheimer's is On: These Are the Forerunners

Top pharmaceutical companies are paving the way to a cure for Alzheimer's, a degenerative disease that is affecting millions around the world.

Jim Cramer: We've Got an Extremist Market

Jim Cramer: We've Got an Extremist Market

Don't buy up when there's nothing but rampant pin action.

Biogen Downgraded to Neutral at Baird

2 Small Biotechs I Like in the Second Half

2 Small Biotechs I Like in the Second Half

Adamis Pharmaceuticals and Pieris Pharmaceuticals are names to watch.

Biogen Stock: A Long-Term Bullish Perspective

Biogen Stock: A Long-Term Bullish Perspective

After Friday's surge another look at BIIB is warranted.

Jim Cramer: The Strength in Pharma, Health Care and Real Estate Is Transient

Jim Cramer: The Strength in Pharma, Health Care and Real Estate Is Transient

The seemingly terrific rationales for strength in these economically sensitive sectors seem glib until the bigger global economic issues get resolved.

Video: Jim Cramer on the Jobs Report, Tariffs and Biogen

Video: Jim Cramer on the Jobs Report, Tariffs and Biogen

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Friday's trending market topics from the floor of the New York Stock Exchange.

Biogen, Eisai Aim to Bring Their Alzheimer Drug to Market

Biogen, Eisai Aim to Bring Their Alzheimer Drug to Market

Real Money reveals the crucial component Biogen got right in this trial and what it plans for the drug next.

Biotech Stocks Rally on Biogen's Landmark Test

Biotech Stocks Rally on Biogen's Landmark Test

Investors might be finally recognizing the hidden value of the firms' drug research and development.

Midday Musings

At midday tech, biotech ( dragging the group higher), homebuilders and energy are leading to the upside. There are really no large underperformers - though on a relative sense, autos, cap goods and semis are trailing. Banks fell initially, on the "d...

Biogen: Let the Situation Cool Off a Bit Before Buying

Biogen: Let the Situation Cool Off a Bit Before Buying

There are issues in the study that are keeping some buyers cautious and causing selling into the early strength.

Gilead Sciences Is Displaying a Bullish Long-Term Pattern

Gilead Sciences Is Displaying a Bullish Long-Term Pattern

This biotech's weekly chart is very encouraging.

Exposure to Feverish Biogen Should Give These 2 Biotech ETFs Booster Shots

Exposure to Feverish Biogen Should Give These 2 Biotech ETFs Booster Shots

First Trust NYSE Arca Biotechnology Index Fund and iShares Nasdaq Biotechnology ETF look like two ways to catch the rally in Biogen.

Biogen Soars, and It May Signal a Breakout Gap to Further Gains

Biogen Soars, and It May Signal a Breakout Gap to Further Gains

My longer-term price target is now $416.

Biogen Upgraded to Buy at Canaccord

Biogen Can Do More For the Bulls

Biogen Can Do More For the Bulls

Charts suggest that shares of Biogen have farther to run.

Emboldened By Biotech Names

Emboldened By Biotech Names

For the trade, I'm opting to use the iShares Nasdaq Biotechnology ETF.

Biogen Is Set for a Tradable Rally

Biogen Is Set for a Tradable Rally

BIIB looks like it can rally at least 10% from here.

Video: Jim Cramer on Tesla, Biogen, Celgene and Groupon

Video: Jim Cramer on Tesla, Biogen, Celgene and Groupon

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Friday's trending stocks from the floor of the New York Stock Exchange.

Here's My Take on Biotech Stocks

Here's My Take on Biotech Stocks

I think M&A activity will pick up markedly going forward across the industry.

Video: Jim Cramer Reacts to Novartis' Acquisition of AveXis

Video: Jim Cramer Reacts to Novartis' Acquisition of AveXis

Novartis agreed to acquire AveXis for $8.7 billion on Monday. TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts.

Biogen Is In a Downtrend With Further Risk Ahead

Biogen Is In a Downtrend With Further Risk Ahead

Charts are signalling more trouble ahead for the stock.